Vascular Cardiotoxicity of Ponatinib

Vascular Cardiotoxicity of Ponatinib

Pre-clinical studies suggest that the third generation tyrosine kinase inhibitor ponatinib can result in microvascular angiopathy and acceleration of atherosclerosis. This study is intended to examine for myocardial microvascular angiopathy and changes in carotid plaque in patients receiving ponatinib as part of their clinical care.

In this study, we will perform serial echocardiography for ventricular function, myocardial contrast echocardiography for microvascular perfusion assessment, blood analysis for myocardial injury, and carotid US for plaque or IMT progression in subjects receiving ponatinib. This series of tests is intended to provide information on the presence of clinically-evident or subclinical microvascular angiopathy and plaque acceleration.

Inclusion Criteria:

• Diagnosis of CML or ALL
• Prescribed ponatinib

Exclusion Criteria:

• pregnancy or lactation
• major medical illness involving the heart or vasculature (CAD, PAD, DCM).
• hemodynamically unstable
• allergy to ultrasound contrast agents.